Metronomic maintenance therapy (MMT) and prevention of relapses in patients with triple-negative breast cancer (TNBC)? A retrospective analysis.

e12037 Background: In-spite of increased chemo-sensitivity, except for TNBC patients (Pts) with pCR after neo-adjuvant chemotherapy who do extremely well, most Pts with residual disease eventually relapse. This may be because of lack of effective maintenance therapy for TNBC Pts with residual disease. We present a retrospective analysis of consecutive Pts with TNBC treated at BKLWH, the rural outreach center of TMC, wherein the outcome of TNBC Pts receiving MMT was compared to historical control group who did not receive the same. Methods: After standard CAF X 6 based therapy, TNBC Pts were either observed (Sept 2003 to Nov 2011) or received MMT (Nov 2008 to Jun 2013).MMT consisted of 2 phases: initial 12 weeks of daily oral celecoxib (200 mg BD) and cyclophosphamide (50 mg OD) along with 12 doses of weekly IV cisplatin (25 mg/m2). This was followed by 1 year of Phase II maintenance consisting of oral daily metformin (500 mg BD), cyclophosphamide (50 mg OD) along with weekly methotrexate (12 mg/m2). Resul...